On one hand, this enables TCR-engineered T-cells to recognize both surface and intracellular antigens through MHC antigen presentation which is advantageous over CAR T-cells, but it is accompanied by several downsides including inefficacy upon MHC downregulation on tumor cells [64] and mispairing of engineered TCRs with autologous TCRs which can potentially lead to unexpected adverse events [65]. Here, HLA-C is linked to neoplasm.